Clinical trials: Cancer-associated Thrombosis, open to volunteers
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Renal Cancer, Kidney Cancer
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
The primary objective of this study is to evaluate whether the combination of Pembrolizumab and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor Thrombus burden.
- Conditions
- Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
- Trial name
- NEOPAX (NCT05969496)
- Testing
- Axitinib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Cardiovascular Diseases, Arterial Thrombosis
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and are now approved for various types of cancer. The most common side effects of ICI are immune-related adverse events which can affect any organ or system…
- Conditions
- Cardiovascular Diseases, Arterial Thrombosis, Myocardial Infarction, Stroke
- Trial name
- ITHACA (NCT06519292)
- Testing
- Coronary computed tomography angiography (CCTA) at baseline, Coronary computed tomography angiography (CCTA) after 1 year
- Where
- Netherlands
- Volunteers
- 214 people
- Sponsor
- Hanneke W. M. van Laarhoven
Superficial Vein Thrombosis, Cancer
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT.
- Conditions
- Superficial Vein Thrombosis, Cancer, Venous Thrombosis
- Trial name
- SUPERCAT (NCT07210671)
- Where
- France
- Volunteers
- 1,576 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism…
- Trial name
- CAN-CATCH (NCT06894576)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Ottawa Hospital Research Institute
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Adult Cancer Patients, Right Atrial Clot
A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer
The researchers are doing this study to see how well cardiac magnetic resonance imaging (CMR) scans can be used to examine the properties of central venous catheter-associated right atrial clot (RA clot).
- Trial name
- NCT07549477
- Testing
- Cardiac MRI
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Venous Thromboembolism, Metastatic Pancreatic Cancer
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
- Conditions
- Venous Thromboembolism, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- CATIQ P3 (NCT06861088)
- Testing
- Kinisoquin™
- Where
- 3 sites in United States
- Volunteers
- 480 people
- Sponsor
- Quercis Pharma AG
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma with PVTT
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus half-dose donafenib (a kind of anti-angiogenesis agents) in advanced hepatocellular carcinoma (BCLC-C…
- Trial name
- DoTH (NCT06646198)
- Testing
- Transjugular intrahepatic portosystemic shunt (TIPS), Donafenib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fei Gao
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 14 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
PICC-associated Thrombosis
Construction and Multicenter External Validation of an Early Warning Model for Asymptomatic PICC-related Upper Extremity Venous Thrombosis in Cancer Patients Based on LASSO-XGBoost
You will be invited to participate in a clinical study. This informed consent form provides you with some information to help you decide whether to participate in this clinical study. Please read carefully.
- Trial name
- NCT07906912
- Testing
- color Doppler ultrasonography
- Volunteers
- 1,655 people
- Sponsor
- Zhongnan Hospital
Cancer-Associated Thrombosis (CAT)
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
- Trial name
- ROXI-CAT-I (NCT07410117)
- Testing
- REGN7508
- Where
- 28 sites in United States, Georgia and 1 more
- Volunteers
- 1,120 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism, Deep Venous Thrombosis
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant…
- Trial name
- NCT07399977
- Testing
- MSK-ACCESS, ctDNA/VTE Risk Score:
- Where
- 8 sites in United States, Australia
- Volunteers
- 259 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thromboembolism, Cancer
Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica"
Epidemiological, observational, non-interventional, multicentric study on patients diagnosed with cancer who develop a venous or arterial thromboembolic episode, symptomatic or incidental, within a month prior to cancer diagnosis…
- Trial name
- TESEO (NCT03855592)
- Where
- 48 sites in Spain
- Volunteers
- 700 people
- Sponsor
- Fundación Sociedad Española de Oncologia Médica
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Venous Thromboembolism, Cancer
Statins to Prevent Cancer Associated Blood Clots
Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks.
- Conditions
- Venous Thromboembolism, Cancer, Cardiovascular Events
- Trial name
- STAT-CAT (NCT07303816)
- Testing
- Rosuvastatin
- Where
- 9 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- Brigham and Women's Hospital
Cancer, Pulmonary Embolism
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Pulmonary embolism, the second leading cause of death in cancer patients, is effectively treated with anticoagulants. In patients with cancer-associated thrombosis (CAT), the use of anticoagulants is associated with 10 to 15% of…
- Conditions
- Cancer, Pulmonary Embolism, Thrombosis
- Trial name
- CATforCAT (NCT06386107)
- Testing
- Thrombin Generation Assay (TGA)
- Where
- 4 sites in France
- Volunteers
- 212 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Cancer-associated Thrombosis, Thrombocytopenia
STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding.
- Trial name
- NCT05255003
- Testing
- Enoxaparin, Dalteparin, Tinzaparin
- Where
- 4 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Tzu-Fei Wang